June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company’s transcatheter mitral and tricuspid programs, presented as part of the late-breaking clinical trials at EuroPCR and ACC 2021. Both valve programs demonstrated positive outcomes for patients impacted by mitral or tricuspid heart valve disease.
The structural heart device clinical data presentations provided the following updates:
• The 30-day outcomes from the TRISCEND study of the transfemoral Evoque tricuspid valve replacement system demonstrated technical feasibility and an acceptable safety profile, along with improvements in tricuspid regurgitation (TR) and symptoms in patients with clinically significant TR. The favorable 30-day results showed high device and procedural success rates of 98% and 94%, respectively, and significant reduction in TR severity, with 98% of patients experiencing mild or less.